Xian Wang1*, Canbin Zhang1, Ziqiang Shang1, Dong Yang1, Mengmeng Li2, Ningning Luo2 and Yaqing Wu2
1Department of Thoracic Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Henan University of Science and Technology, China
2The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, China
Background: Anaplastic Lymphoma Kinase (ALK) re arrangement is observed in about 3% to 7% lung Adenocarcinoma (ADC). With the development of Next-Generation Sequencing (NGS) technology, more novel ALK fusions have been discovered, which can provide patients more opportunities to receive target therapies and achieve clinical effects. Case Report: A case of an invasive lung ADC patient with micropapillary and solid patterns harboring a novel ALK fusion (ME1-ALK) was reported. Then, thoracoscopic resection of right upper lung and cautery division of pleural adhesions were performed with general anesthesia. Considering that solid and micropapillary components accounted for 50%, nedaplatin plus pemetrexed were administrated for 4 cycles after operation with the patient's consent. The patient had no recurrence and the Disease Free Survival (DFS) was 10 months by May 17th, 2021. Conclusion: This case highlights that NGS profiling can identify more novel fusions and help solid/ micropapillary-lung ADC patients find more opportunities to receive target therapies if the patient recurrence.
Invasive lung adenocarcinoma; Solid/micropapillary components; ME1-ALK fusion
Wang X, Zhang C, Shang Z, Yang D, Li M, Luo N, et al. A Novel ME1- ALK Fusion Identified in an Invasive Lung Adenocarcinoma Patient with Micropapillary and Solid Patterns: Case Report. Ann Clin Case Rep. 2021; 6: 2026..